RemeGen’s telitacicept, the world’s first approved fusion protein targeting B-cell lymphocyte stimulator/a proliferation inducing ligand (BLyS/APRIL), is looking increasingly likely to provide a strong alternative to existing neonatal Fc receptor (FcRn) inhibitors in generalized myasthenia gravis (gMG), new data from a China-only Phase III study suggest.
Key Takeaways
- RemeGen’s telitacicept looks likely to be a strong alternative to FcRn inhibitors such as argenx’s Vyvgart for generalized myasthenia gravis, based on new data from a China Phase III study.
At week 24, patients treated with telitacept subcutaneously once weekly showed improvements of a placebo-adjusted 4.8 points (p<0.001) in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?